Dechra Pharmaceuticals PLC Logo

Dechra Pharmaceuticals PLC

Develops & sells veterinary pharmaceuticals for companion animals, exclusively to veterinarians.

DPH | IL

Overview

Corporate Details

ISIN(s):
US2434351043
LEI:
213800J4UVB5OWG8VX82
Country:
United Kingdom
Address:
24 CHESHIRE AVENUE, CW9 7UA NORTHWICH
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dechra Pharmaceuticals PLC is a global specialist in veterinary pharmaceuticals and related products. The company focuses on the development, manufacture, marketing, and sales of high-quality products designed to improve animal health and welfare. Its portfolio includes a range of drugs and therapies for the prevention, diagnosis, and treatment of conditions in animals, with a focus on companion animals like dogs, cats, and horses. Dechra markets its products exclusively to veterinarians worldwide, positioning itself as a dedicated partner to the profession. The company also provides educational support through resources like the Dechra Academy to help veterinary professionals stay current with industry advancements.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-01-23 17:41
Major Shareholding Notification
Holding(s) in Company
English 23.4 KB
2024-01-18 16:14
Major Shareholding Notification
Holding(s) in Company
English 21.7 KB
2024-01-18 11:11
Major Shareholding Notification
Holding(s) in Company
English 26.8 KB
2024-01-17 15:01
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2024-01-17 13:01
Delisting Announcement
Holding(s) in Company
English 51.4 KB
2024-01-17 13:00
Major Shareholding Notification
Holding(s) in Company
English 54.9 KB
2024-01-17 12:16
Major Shareholding Notification
Holding(s) in Company
English 29.1 KB
2024-01-17 09:15
Delisting Announcement
Cancellation of listing and admission to trading
English 24.9 KB
2024-01-17 08:30
Major Shareholding Notification
Holding(s) in Company
English 21.6 KB
2024-01-16 17:54
Major Shareholding Notification
Holding(s) in Company
English 22.5 KB
2024-01-16 16:25
Major Shareholding Notification
Form 8.3 - Dechra Pharmaceuticals plc
English 46.1 KB
2024-01-16 15:43
Major Shareholding Notification
Holding(s) in Company
English 31.2 KB
2024-01-16 13:04
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2024-01-16 11:15
AGM Information
Scheme of Arrangement becomes Effective
English 45.8 KB
2024-01-16 10:00
Major Shareholding Notification
Holding(s) in Company
English 29.7 KB

Automate Your Workflow. Get a real-time feed of all Dechra Pharmaceuticals PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dechra Pharmaceuticals PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dechra Pharmaceuticals PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CHOSA Oncology AB Logo
Develops diagnostics and targeted therapies to personalize platinum-based cancer treatments.
Sweden
CHOSA
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
CHUKYOIYAKUHIN CO.,LTD. Logo
Direct-to-home service providing medicine boxes, health products, and daily necessities.
Japan
4558
Cidara Therapeutics, Inc. Logo
Developing drug-Fc conjugates as targeted immunotherapies for cancer and serious infections.
United States of America
CDTX
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.